Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 7/20 | 0.56 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.55 |
| ▸ | ELANE | P08246 | 2/20 | 0.54 |
| ▸ | CTSS | P25774 | 6/20 | 0.53 |
| ▸ | CTSL | P07711 | 5/20 | 0.53 |
| ▸ | CTSB | P07858 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15691158 | 1.00 | ATM (0.58) | ATMCTSKCTRB1ELANECTSS | |
| SCHEMBL15691079 | 1.00 | ATM (0.58) | ATMCTSKCTRB1ELANECTSS | |
| SCHEMBL6140023 | 0.87 | ATM (0.61) | ATMCTSKCTRB1ELANECTSS | |
| SCHEMBL12942877 | 0.87 | ATM (0.61) | ATMCTSKCTRB1ELANECTSS | |
| SCHEMBL6841166 | 0.87 | ATM (0.61) | ATMCTSKCTRB1ELANECTSS | |
| SCHEMBL14704026 | 0.87 | ATM (0.61) | ATMCTSKCTRB1ELANECTSS | |
| Hydrochloric Acid SCHEMBL5741994 | 0.86 | ATM (0.59) | ATMCTSKCTRB1ELANECTSS | |
| SCHEMBL15691156 | 0.86 | CTSS (0.61) | ATMCTSKCTRB1ELANECTSS | |
| SCHEMBL6841165 | 0.86 | CTSS (0.61) | ATMCTSKCTRB1ELANECTSS | |
| SCHEMBL20869899 | 0.85 | CTSL (0.57) | ATMCTSKCTRB1ELANECTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210169905-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20200046738-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-20180325923-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2018-11-15 | — | — | US | disclosed |
| EP-2315740-B1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2813486-B1 | Fatty acid acetylated salicylates and their uses | CATABASIS PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2315740-B1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2813486-B1 | Fatty acid acetylated salicylates and their uses | CATABASIS PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170246193-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170246193-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170246193-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20120238585-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238586-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8173831-B2 | Fatty acid acetylated salicylates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173831-B2 | Fatty acid acetylated salicylates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| EP-2315740-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | Catabasis Pharmaceuticals, Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20100184730-A1 | Fatty Acid Acylated Salicylates and Their Uses | CATABASIS PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184730-A1 | Fatty Acid Acylated Salicylates and Their Uses | CATABASIS PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100041748-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20100041748-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| WO-2010006085-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200046738-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | ATM 2658/4885CTSK 1941/4885CTRB1 3406/4885 |
| US-20120238585-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | ATM 2658/4885CTSK 1941/4885CTRB1 3406/4885 |
| US-20180325923-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | ATM 2658/4885CTSK 1941/4885CTRB1 3406/4885 |
| US-20120238586-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | ATM 2658/4885CTSK 1941/4885CTRB1 3406/4885 |
| US-20170246193-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | ATM 2658/4885CTSK 1941/4885CTRB1 3406/4885 |
| US-20100041748-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | ATM 2658/4885CTSK 1941/4885CTRB1 3406/4885 |
| US-20210169905-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | ATM 2658/4885CTSK 1941/4885CTRB1 3406/4885 |
| US-20100184730-A1 | Fatty Acid Acylated Salicylates and Their Uses | FADS1, FASN, ALOX5 | ATM 3836/4885CTSK 2333/4885CTRB1 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.